$0.90
0.82% yesterday
Nasdaq, Sep 03, 10:04 pm CET
ISIN
US74039M1018
Symbol
POAI

Predictive Oncology Inc Stock price

$0.90
+0.13 16.28% 1M
-0.36 28.57% 6M
+0.08 9.76% YTD
-0.03 3.36% 1Y
-6.96 88.55% 3Y
-16.90 94.94% 5Y
-18,448.60 100.00% 10Y
+0.75 500.00% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.01 0.82%

Key metrics

Basic
Market capitalization
$9.9m
Enterprise Value
$9.6m
Net debt
positive
Cash
$510.0k
Shares outstanding
9.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.2 | 1.0
EV/Sales
9.0 | 1.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-4.1%
Return on Equity
6,250.9%
ROCE
2,288.9%
ROIC
-
Debt/Equity
-0.2
Financials (TTM | estimate)
Revenue
$1.1m | $9.5m
EBITDA
$-9.2m | -
EBIT
$-9.4m | $-1.9m
Net Income
$-9.8m | $-1.3m
Free Cash Flow
$-9.4m
Growth (TTM | estimate)
Revenue
-38.9% | 487.7%
EBITDA
32.8% | -
EBIT
33.4% | 82.7%
Net Income
30.3% | 90.0%
Free Cash Flow
26.7%
Margin (TTM | estimate)
Gross
48.5%
EBITDA
-863.3% | -
EBIT
-876.8%
Net
-913.5% | -13.4%
Free Cash Flow
-878.4%
More
EPS
$-1.1
FCF per Share
$-1.0
Short interest
2.3%
Employees
24
Rev per Employee
$70.0k
Show more

Is Predictive Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Predictive Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Predictive Oncology Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Predictive Oncology Inc forecast:

Hold
50%
Sell
50%

Financial data from Predictive Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1.07 1.07
39% 39%
100%
- Direct Costs 0.55 0.55
21% 21%
51%
0.52 0.52
51% 51%
49%
- Selling and Administrative Expenses 7.44 7.44
29% 29%
695%
- Research and Development Expense - -
-
-
-9.24 -9.24
33% 33%
-864%
- Depreciation and Amortization 0.15 0.15
56% 56%
14%
EBIT (Operating Income) EBIT -9.38 -9.38
33% 33%
-877%
Net Profit -9.78 -9.78
30% 30%
-914%

In millions USD.

Don't miss a Thing! We will send you all news about Predictive Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Predictive Oncology Inc Stock News

Neutral
GlobeNewsWire
15 days ago
NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a new...
Neutral
GlobeNewsWire
21 days ago
PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June ...
Neutral
GlobeNewsWire
about 2 months ago
PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement (“SEPA”) with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”). Predictive Oncology expects the partnership to provide an efficient and flexible source of ...
More Predictive Oncology Inc News

Company Profile

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Domestic, International, and Helomics. The Domestic and International segments focuses on STREAMWAY System product sales. The Helomics segment comprises of clinical testing and contract research. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.

Head office United States
CEO Raymond Vennare
Employees 24
Founded 2002
Website predictive-oncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today